Efficacy and Safety of Thoracic Radiotherapy in Locally Advanced Non-Small Cell Lung Cancer Patients With Pre-Existing Interstitial Lung Diseases: A Single Center Experience of 85 Cases

Abstract

<h3>Purpose/Objective(s)</h3> Whether thoracic radiotherapy (TRT) could be applied to interstitial lung diseases and lung cancer (ILD-LC) patients safely remains unclear. This retrospective study aims to evaluate the efficacy and safety of definitive TRT in locally advanced non-small cell lung cancer (LA-NSCLC) patients with pre-existing ILD, and to analyze the associated risk factors for radiation induced lung toxicities (RILTs) in the clinical setting. <h3>Materials/Methods</h3> Patients with histologically confirmed LA-NSCLC and pre-existing ILD treated definitive TRT between 2010 and 2019 were retrospectively reviewed. Patient, tumor, and treatment characteristics were evaluated to determine the risk factors for RILTs. Pre-radiation CT of all patients were reviewed by two radiologists and one pulmonologist and are scored according to Müller's thin-section CT scoring system for IPF: 0-no discrete honeycombing, with interlobular septal thickening; 1-honeycombing involving 0-5% of the lobe; 2-honeycombing 6-24%; 3-honeycombing 25-49%; 4-honeycombing 50-74%;5-honeycombing > 75%. Univariate and multivariate analyses with logistic regression models and cox proportional hazards approach were performed to identify the risk factor(s) of RILTs and overall survival (OS) respectively. <h3>Results</h3> Among 1261 LA-NSCLC patients, 85 were found with pre-existing ILD and enrolled in the analysis. 36.5% of them were scored more than 1 point on CT. 20% patients developed G3+ RILTs within 1 year after the last irradiation, with remarkably 11.8% dying from lung toxicities. And the incidence of symptomatic (G3+) RILTs abruptly dropped to 11.1% (6/54), 3.8% (1/26), and 0% (0/19) for patients with CT score ≤1, V20 < 20%, or neither, respectively. Multivariate analysis showed that CT score > 1 and V20 ≥ 20% were independently associated with higher risk of G3+ RILTs. The median OS and PFS were 14.0 months and 7.4 month respectively. In the univariate analysis for OS, clinical stage and G3+RILT were evaluated as risk factors while patients in low-risk group, defined as honeycombing score < 1 and V20 < 20%, had shown a protective tendency (HR = 0.52, 95% CI: 0.27-1.04, <i>P</i> = 0.063). In multivariate analysis, G3+RILT was the only independent risk factor associated with OS (HR = 2.40, 95% CI: 1.32-4.36, <i>P</i> = 0.004). However, the median OS of low-risk group was quite longer than the whole group (26.5 months versus 14.5 months), indicating that patients at low risk might benefit from thoracic radiation therapy. <h3>Conclusion</h3> Honeycombing score > 1 and V20 ≥ 20% were significantly associated with high incidence of severe lung toxicities, leading to poor survival. However, patients at low risk might benefit from TRT with a considerable overall survival.